Overview

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Status:
Active, not recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Phase:

Phase 3

Details

Lead Sponsor:

Intercept Pharmaceuticals

Treatments:

Chenodeoxycholic Acid